CTCL

The EMA grants MRG-106 Orphan Drug Designation for Cutaneous T-Cell Lymphoma

On 24th May 2017, the European Medicines Agency (EMA) granted Orphan Drug Designation status to MRG-106 for the treatment of patients with CTCL.

miRagen Therapeutics’ MRG-106 is an inhibitor of miR-155, which is elevated in malignant T-cells. MiR-155 is a key player in a range of normal and malignant cell pathways and processes, and potentially contributes to CTCL cell progression and survival.

A phase I trial (NCT02580552) of MRG-106 in Mycosis Fungoides type CTCL (MF-CTCL) is currently being carried out; results will be presented during this year’s American Society of Clinical Oncology Annual Meeting, taking place in Chicago between 2nd–6th June.

MRG-106 also holds Orphan Drug Designation for Mycosis Fungoides type CTCL from the U.S. Food and Drug Administration (FDA), awarded in March 2017.

Reference:
  1. Lymphoma News Today. EU Gives Orphan Drug Status to MRG-106 for Treating T-cell Skin Lymphomas. 2017 May 26. https://lymphomanewstoday.com/2017/05/26/eu-grants-orphan-drug-status-to-skin-lymphoma-therapy-mrg-106/. [Accessed 2017 May 30].